The number of older Americans treated for prostate cancer plummeted 42 percent since health officials began questioning the benefits of screening tests, a new study shows. The finding points to the success of efforts to curtail the use of controversial prostate-specific antigen, or PSA, screening tests, said lead author Dr. Tudor Borza.